TITLE

Off-label use, complex trials affect renal artery stenting

AUTHOR(S)
Rusk, Judith
PUB. DATE
November 2008
SOURCE
Cardiology Today;Nov2008, Vol. 11 Issue 11, p1
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article considers experts' views on off-label use of available renal artery stents and complicated trials of patients with hypertension. Dr. David Buckles of the U.S. Food and Drug Administration (FDA) states that physicians can use legally-marketed device off-label or enroll patients in clinical trials and physicians often used the off-label device. Interventional radiology professor John Kaufman blames the industry, physicians, patients, health insurers and regulatory agencies for the lack of evidence in renal artery stenting.
ACCESSION #
35639335

 

Related Articles

  • BSC GETS IDE APPROVAL TO BEGIN TAXUS IV CLINICAL TRIAL.  // Biotech Equipment Update;May2002, p5 

    The article reports that Boston Scientific Corp. has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to begin its TAXUS IV clinical trial. Boston Scientific acquired worldwide co-exclusive rights from Angiotech to use paclitaxel to coat its...

  • Endeavor DES garners panel thumbs-up.  // Medical Technology & Devices Week;10/15/2007, Vol. 5 Issue 41, p5 

    The article reports on the premarket approval given by the U.S. Food and Drug Administration (FDA) to Medtronic's Endeavor, a second-generation drug-eluting stent (DES). The FDA approved the DES based on data of seven clinical trials that were provided by Medtronic to the circulatory system...

  • Medtronic begins enrollment in Complete SE stent study.  // Medical Device Daily;1/6/2009, Vol. 13 Issue 2, p8 

    The article reports on the first enrollment in Medtronic's U.S. Food and Drug Administration (FDA)-approved clinical trial of its self-expanding (SE) Complete SE stent for the treatment of peripheral arterial disease (PAD) in the superfacial femoral artery (SFA). It is noted that the SFA study...

  • Charge of the 900; Cook will need hundreds more for PAS. McCARTY, MARK // Medical Device Daily;10/17/2011, Vol. 15 Issue 198, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) advisory committee has instructed Cook Medical to conduct a post-approval study (PAS) with 900 enrollees as a prerequisite for approval of the firm's Zilver PTX drug-eluting stent for the femoropopliteal artery. The PAS is...

  • Tryton enrolls first patient in side stent system study. FORD, OMAR // Medical Device Daily;1/27/2011, Vol. 15 Issue 18, p1 

    The article reports on the application of Tryton Medical for U.S. Food and Drug Administration (FDA) approval for its side branch system designed to treat bifurcation lesions. The company said that the first U.S. patient has been enrolled in the trial to evaluate the system. The trial will...

  • With Xience launched, Abbott begins post-approval study. Pedersen, Amanda // Medical Device Daily;7/11/2008, Vol. 12 Issue 133, p1 

    The article reports on the preparations of medical device company Abbott for the clinical trial of the Xience V everolimus-eluting coronary stent after the approval of the device by the U.S. Food and Drug Administration (FDA) in July 2008. The study will evaluate the device's safety and...

  • Boston Sci completes enrollment in EVOLVE II.  // Medical Device Daily;9/16/2013, Vol. 17 Issue 178, p9 

    The article reports on the completion of the enrollment of the EVOLVE II randomized, controlled clinical trial involving the Synergy Stent System by medical device manufacturer Boston Scientific Corp.

  • IDEV completes SUPERB Clinical Trial Enrollment.  // Biotech Equipment Update;Jul2011, Vol. 16 Issue 7, p1 

    The article reports on the completion of Idev Technologies Inc. to its enrollment in the SUPERB Trial, an approved investigational device exemption (IDE) trial of the U.S. Food and Drug Administration (FDA). It indicates that the trial aims to examine the use of the company's SUPERA stent system...

  • Abbott launches trial to study women-only effects of DES use. Pedersen, Amanda // Cardiovascular Device Update;Aug2007, Vol. 13 Issue 8, p9 

    The article reports on the Xience V Spirit Women clinical trial launched by Abbott Vascular. The aim of the clinical trial is to determine the effects of drug-eluting stents (DES) in women. The trial will use the company's Xience V Everolimus Eluting Coronary Stent System which is being reviewed...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics